Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lysocin E
- Development stage
- Preclinical
- Lead developer
- Yamagata University
- Modality
- Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
Lysocin E is a novel cyclic lipopeptide (specifically a 37-membered depsipeptide) antibiotic originally isolated from the soil bacterium *Lysobacter* sp. strain RH2180-5. It exhibits potent, rapid bactericidal activity against Gram-positive pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA) and *Mycobacterium tuberculosis*. Lysocin E exerts its antibacterial effect through a unique mechanism of action, directly binding to menaquinone (vitamin K2) in the bacterial cell membrane, which leads to membrane disruption, respiratory chain inhibition, and rapid cell lysis. It has demonstrated robust therapeutic efficacy in various animal models of infection, including silkworm and mouse models.
- Other names
- CAS 1219370-30-5CAS1219370-30-5CAS-1219370-30-5
02
Targets
Lipid II
Beyond the preview
Go deeper on lysocin E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lysocin E.